TY - JOUR
T1 - Application of the updated International IgA Nephropathy Prediction Tool in children one or two years post-biopsy
AU - International IgA Nephropathy Network Research Group
AU - Barbour, Sean J.
AU - Coppo, Rosanna
AU - Er, Lee
AU - Russo, Maria Luisa
AU - Liu, Zhi Hong
AU - Ding, Jie
AU - Zhong, Xuhui
AU - Katafuchi, Ritsuko
AU - Yoshikawa, Norishige
AU - Xu, Hong
AU - Kagami, Shoji
AU - Yuzawa, Yukio
AU - Emma, Francesco
AU - Cambier, Alexandra
AU - Peruzzi, Licia
AU - Wyatt, Robert J.
AU - Cattran, Daniel C.
AU - Zeng, Caihong
AU - Su, Biage
AU - Nakanishi, Koichi
AU - Zhai, Yihui
AU - Urushihara, Maki
AU - Hattori, Motoshi
AU - Camassei, Francesca Diomedi
AU - Barreca, Antonella
AU - Robert, Thomas
AU - Prikhodina, Larisa
AU - Berg, Ulla
AU - Topaloglu, Rezan
AU - Mizerska-Wasiak, Malgorzata
AU - Papagianni, Aikaterini
AU - Bellur, Shubha S.
AU - Roberts, Ian
N1 - Publisher Copyright:
© 2024 International Society of Nephrology
PY - 2024/11
Y1 - 2024/11
N2 - The pediatric International IgA Nephropathy (IgAN) Prediction Tool comprises two models with and without ethnicity and is the first method to predict the risk of a 30% decline in estimated glomerular filtration rate (eGFR) or kidney failure in children at the time of biopsy using clinical risk factors and Oxford MEST histology scores. However, it is unknown if the Prediction Tool can be applied after a period of observation post-biopsy. Using an international multi-ethnic cohort of 947 children with IgAN, 38% of whom were followed into adulthood, the Prediction Tool was updated for use one year after biopsy. Compared to the original pediatric Prediction Tool, the updated post-biopsy Prediction Tool had a better model fit with higher R2D (51%/50% vs 20%), significant increase in 4-year C-statistics (0.83 vs 0.73/0.69, ΔC 0.09 [95% confidence interval 0.07-0.10] and ΔC 0.14 [0.12-0.15]) and better 4-year calibration with lower integrated calibration indices (0.74/0.54 vs 2.45/1.01). Results were similar after internal validation and when the models were applied two years after biopsy. Trajectories of eGFR after a baseline one year post-biopsy were non-linear and those at higher predicted risk started with a lower eGFR and experienced a more rapid decline over time. In children, eGFR had a variable rate of increase until 15-18 years old and then decreased linearly with a more rapid decline in higher risk groups that was similar to young adults of comparable risk. Thus, the original pediatric Prediction Tool should be used in children at the time of biopsy, and the updated pediatric Prediction Tool should be used to re-evaluate risk one or two years after biopsy.
AB - The pediatric International IgA Nephropathy (IgAN) Prediction Tool comprises two models with and without ethnicity and is the first method to predict the risk of a 30% decline in estimated glomerular filtration rate (eGFR) or kidney failure in children at the time of biopsy using clinical risk factors and Oxford MEST histology scores. However, it is unknown if the Prediction Tool can be applied after a period of observation post-biopsy. Using an international multi-ethnic cohort of 947 children with IgAN, 38% of whom were followed into adulthood, the Prediction Tool was updated for use one year after biopsy. Compared to the original pediatric Prediction Tool, the updated post-biopsy Prediction Tool had a better model fit with higher R2D (51%/50% vs 20%), significant increase in 4-year C-statistics (0.83 vs 0.73/0.69, ΔC 0.09 [95% confidence interval 0.07-0.10] and ΔC 0.14 [0.12-0.15]) and better 4-year calibration with lower integrated calibration indices (0.74/0.54 vs 2.45/1.01). Results were similar after internal validation and when the models were applied two years after biopsy. Trajectories of eGFR after a baseline one year post-biopsy were non-linear and those at higher predicted risk started with a lower eGFR and experienced a more rapid decline over time. In children, eGFR had a variable rate of increase until 15-18 years old and then decreased linearly with a more rapid decline in higher risk groups that was similar to young adults of comparable risk. Thus, the original pediatric Prediction Tool should be used in children at the time of biopsy, and the updated pediatric Prediction Tool should be used to re-evaluate risk one or two years after biopsy.
KW - IgA nephropathy
KW - chronic kidney disease
KW - glomerulonephritis
UR - https://www.scopus.com/pages/publications/85202958759
UR - https://www.scopus.com/pages/publications/85202958759#tab=citedBy
U2 - 10.1016/j.kint.2024.07.012
DO - 10.1016/j.kint.2024.07.012
M3 - Article
C2 - 39094695
AN - SCOPUS:85202958759
SN - 0085-2538
VL - 106
SP - 913
EP - 927
JO - Kidney International
JF - Kidney International
IS - 5
ER -